August 22, 2017 10:37 AM EDTUpdated 11:01 AM
News Briefing

In­di­v­ior opens up a $30M R&D cen­ter; Lil­ly strikes dis­cov­ery deal with Topas

Shehla Shakoor

Managing Director

⇨ Eli Lil­ly $LLY has turned to Ger­many’s Topas Ther­a­peu­tics for a new dis­cov­ery deal cov­er­ing drugs for in­flam­ma­to­ry or au­toim­mune con­di­tions. As part …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times